GnRH is defined as the hormone that regulates the pituitary and is secreted by the brain’s hypothalamus. It is regulated by the hypothalamus and controls the secretion of LH and FSH from the pituitary. Additionally, GnRH controls the target gland’s release of androgen, estrogen, and progestin.
Pituitary stimulation with pulsatile gonadotropin-releasing hormone (GnRH) analogs induces both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Pituitary gonadotropin secretions are blocked upon desensitization when a sustained GnRH stimulus is provided by an agonist or when pituitary receptors are occupied by a competitive antagonist. (1)
If the ovulatory cycle cannot be controlled and the eggs are released early, they cannot be collected and fertilized in the embryology laboratory. For this reason, an IVF doctor in Turkey may recommend that you take a GnRH agonist or a GnRH antagonist.
What is the GnRH antagonist?
In Assisted Reproductive Technologies (ART), the development of GnRH antagonists (GnRH-ant) to inhibit LH surge appeared to pave the way for a more “friendly” IVF. GnRH antagonists prevent the first excitatory phase of agonists by immediately suppressing pituitary gonadotropin through GnRH-receptor competition. The pituitary-gonadal axis recovers quickly and predictably after GnRH antagonist treatment is stopped. (2)
What is the aim of GnRH antagonists for IVF?
GnRH antagonists are used in IVF to prevent an early LH release that might cause premature luteinization, follicle maturation to stop, and oocyte maturation to mismatch. Although the use of GnRH antagonists in IVF has its disadvantages, the advantages outweigh.
Daily volume control is still possible with GnRH antagonist protocols, and there is still sufficient flexibility regarding timeframes. However, this can be improved by utilizing the oral contraceptive pill (OCP). (3)
What is GnRH agonist?
In GnRH antagonist cycles, the GnRH agonist is employed to initiate eventual oocyte maturation. GnRH agonist induces an LH surge that is not identical to that occurring in the natural cycle, especially regarding its duration. (4)
HCG replacement with a GnRH agonist in high-risk IVF patients may lessen the possibility that they would experience ovarian hyperstimulation syndrome (OHSS). On the other hand, a reduced probability of pregnancy is linked to replacing human chorionic gonadotropin (HCG) with a GnRH agonist to trigger final oocyte maturation. (5)
GnRH agonists are more powerful and have a longer half-life than native GnRH. They cause the pituitary gonadotropes to release follicle-stimulating hormone (FSH), luteinizing hormone (LH), and other gonadal hormones as the initial stimulation for the anticipated gonadal response. The pituitary-gonadal axis is downregulated and inhibited as a result of this reaction. (6)
What is the aim of GnRH agonists for IVF?
In reproductive technologies, GnRH agonists are used in a wide range of treatment options. Their start and persistence vary, particularly in intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) with ovarian hyperstimulation.
One of the key advantages of the long protocol of GnRH agonist administration for IVF is that initiation of exogenous gonadotropins can be delayed after pituitary desensitization to prevent ovum pickup (OPU), without any detrimental effects on IVF results. (7)
For higher clinical pregnancy rate (CPR) GnRH agonists are a great solution to add to IVF/ICSI’s controlled ovarian hyperstimulation (COS) protocols to prevent premature luteinizing hormone (LH) surge when follicles are still immature.
Resources:
1,6,7- Kumar, P., & Sharma, A. (2014). Gonadotropin-releasing hormone analogs: Understanding advantages and limitations. Journal of human reproductive sciences, 7(3), 170.
2- Depalo, R., Jayakrishan, K., Garruti, G., Totaro, I., Panzarino, M., Giorgino, F., & Selvaggi, L. E. (2012). GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reproductive biology and endocrinology, 10, 1-8.
3,4,5- Tarlatzis, B. C., Fauser, B. C., Kolibianakis, E. M., Diedrich, K., Devroey, P., & Brussels GnRH Antagonist Consensus Workshop Group. (2006). GnRH antagonists in ovarian stimulation for IVF. Human reproduction update, 12(4), 333-340.
